Elsevier

The Lancet

Volume 357, Issue 9251, 20 January 2001, Pages 195-196
The Lancet

Fast track — Research Letters
Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England

https://doi.org/10.1016/S0140-6736(00)03594-7Get rights and content

Summary

The UK was the first country to use meningococcal serogroup C conjugate (MCC) vaccines, which were licensed on the basis of immunogenicity and safety data but without a formal efficacy study. Increased surveillance during the first 9 months since introduction has shown that short-term efficacy of the MCC vaccine in England was 97% (95% CI 77-99) for teenagers and 92% (65-98) for toddlers. These early results confirm the superiority of MCC over plain C polysaccharide vaccines, which are ineffective in young children.

References (5)

There are more references available in the full text version of this article.

Cited by (311)

  • Bacterial Meningitis

    2023, Manson's Tropical Diseases, Fourth Edition
  • Invasive Pneumococcal and Meningococcal Disease

    2019, Infectious Disease Clinics of North America
    Citation Excerpt :

    The dramatic increase in serogroup C IMD in the United Kingdom in the 1990s prompted development of the monovalent meningococcal C conjugate vaccine.81 After introduction into the vaccination schedule for infants in 1999, there was a significant decrease in meningococcal C disease with vaccine efficacy of 97% in teenagers and 92% in toddlers and evidence of a herd immunity effect.82 Immunization schedules in the United Kingdom and other countries now reflect evidence of improved efficacy in older children, administering 1 dose of MenC vaccine at 1 year followed by a quadrivalent conjugate vaccine (Men ACWY) at 14 years.

  • Development and pre-clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Neisseria meningitidis serogroup C

    2019, Vaccine
    Citation Excerpt :

    However, PS based meningococcal vaccines are poorly immunogenic in infants, and in addition MenC PS vaccine induces immunologic hyporesponsiveness in adults [1–4]. On the contrary, PS-protein conjugate vaccines are immunogenic in infants and induce long-term protection [1,5–7]. Recent meningitis outbreaks in Africa and an acute shortage of meningococcal C vaccine suggests the need for development of simple, effective and affordable MenC conjugate vaccine [8].

View all citing articles on Scopus
View full text